A plain-English reference for common terms you will see in clinical-trial reports and medical research.
Randomisation
A method used to assign participants to study groups by chance, helping reduce systematic differences between groups.
Placebo
An inactive treatment or control designed to help researchers assess effects that are attributable to the intervention being studied.
Comparator
The treatment, placebo or other reference group against which an intervention is evaluated.
Endpoint
A defined outcome used to assess what happened in a study. Primary endpoints are specified as the main outcomes of interest.
Adverse event
An unwanted medical occurrence reported during a study. An adverse event is not automatically proven to have been caused by the treatment.
Serious adverse event
An adverse event meeting specified seriousness criteria, such as resulting in death, hospitalisation or another medically important outcome.
Confidence interval
A statistical interval that communicates uncertainty around an estimate. Wider intervals generally indicate greater uncertainty.
Statistical significance
A statistical concept used to assess whether an observed result is inconsistent with a specified null hypothesis. It does not by itself establish clinical importance.
Relative vs absolute effect
Relative changes describe proportional differences, while absolute changes describe the actual difference between groups. Both can help put a result in context.
Follow-up
The period during which participants are observed after an intervention or study start. Longer follow-up can provide information that shorter studies cannot.
Intention-to-treat
An analysis approach that generally evaluates participants according to the groups to which they were originally assigned, preserving the benefits of randomisation.
Topline results
An initial summary of key study findings. Topline announcements may precede publication of the complete methods and detailed results.
Retatrutide research context
Retatrutide is an investigational triple hormone receptor agonist being developed by Lilly. Lilly says it remains investigational and is not approved by any regulatory agency. The company's current development programme includes Phase 3 studies across obesity and related conditions.